{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "transcribes",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:Q9NZQ7",
      "entity_text" : "PD-L1",
      "entity_type" : "gene"
    },
    "hypothesis_information" : false,
    "context" : {
      "Species" : [ "taxonomy:10090" ],
      "Cellular_component" : [ "go:GO:0018995" ],
      "Organ" : [ "uberon:UBERON:0002405" ],
      "CellType" : [ "cl:CL:0000910" ]
    }
  },
  "verbose_text" : "Although olaparib is effective in treating Brca1 deficient tumors, PBM tumors treated with olaparib have increased expression of the immune-inhibitory ligand PD-L1 on tumor cells (XREF_SUPPLEMENTARY), consistent with previous observations.",
  "reading_complete" : "2020-08-08T08:51:29Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-08T08:49:03Z",
  "trigger" : "expression",
  "evidence" : [ "expression of the immune-inhibitory ligand PD-L1" ],
  "pmc_id" : "6366450",
  "score" : 0
}